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ABSTRACT
Introduction: The vitamin D recommended doses
during pregnancy differ between societies. The WHO
guidelines do not recommend routine prenatal
supplementation, but they underscore the fact that
women with the lowest levels may benefit most. The
effects of routine supplementation during pregnancy
on maternal and neonatal clinical outcomes have not
been investigated in the Middle East, where
hypovitaminosis D is prevalent. Our hypothesis is that
in Middle Eastern pregnant women, a vitamin D dose
of 3000 IU/day is required to reach a desirable
maternal 25-hydroxyvitamin D [25(OH)D] level, and to
positively impact infant bone mineral content (BMC).
Methods and analysis: This is a multicentre blinded
randomised controlled trial. Pregnant women
presenting to the Obstetrics and Gynaecology clinics
will be approached. Eligible women will be randomised
to daily equivalent doses of cholecalciferol, 600 IU or
3000 IU, from 15 to 18 weeks gestation until delivery.
Maternal 25(OH)D and chemistries will be assessed at
study entry, during the third trimester and at delivery.
Neonatal anthropometric variables and 25(OH)D level
will be measured at birth, and bone and fat mass
assessment by dual-energy X-ray absorptiometry scan
at 1 month. A sample size of 280 pregnant women is
needed to demonstrate a statistically significant
difference in the proportion of women reaching a 25
(OH)D level ≥50 nmol/L at delivery, and a difference in
infant BMC of 6 (10)g, for a 90% power and a 2.5%
level of significance. The proportions of women
achieving a target 25(OH)D level will be compared
between the two arms, using χ2. An independent t test
will be used to compare mean infant BMC between the
two arms. The primary analysis is an intention-to-treat
analysis of unadjusted results.
Ethics and dissemination: The protocol has been
approved by the Institutional Review Board at the
American University of Beirut-Lebanon (IM.GEHF.22).
The trial results will be published in peer-reviewed
medical journals and presented at scientific conferences.
Trial registration number: NCT02434380.
INTRODUCTION
Vitamin D physiology during pregnancy
Pregnancy is characterised by physiological
changes in mineral metabolism, to allow
calcium accretion in the fetal skeleton.1–3
These changes start in the ﬁrst trimester, and
culminate during the third trimester, a
period during which fetal calcium require-
ments increase exponentially.2 Indeed, it is
in anticipation of such requirements that
maternal calcitriol levels increase during
Strengths and limitations of this study
▪ This is the first randomised controlled trial (RCT)
in the Middle East directly addressing the applic-
ability of the Institute of Medicine recommenda-
tions in this specific population, and assessing
the effect of vitamin D supplementation on neo-
natal bone mineral content.
▪ Multiple maternal and neonatal outcomes that
have not been targeted in any previous trial in
pregnancy will be assessed as secondary or
exploratory outcomes; indeed, the results will
guide future research projects in this field.
▪ Vitamin D and other calciotropic hormones will
be measured using the gold standard method,
liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS).
▪ The findings of this trial will help guide the
public health policymaker regarding vitamin D
supplementation in pregnant women and will
allow a step forward in evidence-based recom-
mendations specific to the Middle East.
▪ Results derived from nutrient RCT, specifically
vitamin D supplementation, suffer from several
confounding factors related to the baseline
status, intake of other nutrients, such as calcium
and proteins, and sun exposure, which are diffi-
cult to quantify accurately.
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pregnancy. While the total calcitriol levels double in the
ﬁrst trimester, free calcitriol levels do not increase until
the third trimester and remain so until lactation.2 4
Conversely, parathyroid hormone (PTH) levels decrease
early on and increase back to mid-normal range by
term.2 The total calcium level decreases during preg-
nancy, due to haemodilution, while the ionised calcium
level remains stable.2 Vitamin D binding proteins also
increase during pregnancy secondary to high oestrogen
levels,4 5 but the 25-hydroxyvitamin D (25(OH)D) level,
the single best nutritional indicator of vitamin D status,6
remains stable.7 The changes in calcitriol levels led to the
description of pregnancy as a state of ‘absorptive hyper-
calciuria’.1 2 The above adaptive physiology is key to
safety considerations when using vitamin D supplementa-
tion during pregnancy, as well as to determining key bio-
chemical and hormonal parameters to be monitored.
Maternal vitamin D status during pregnancy
Vitamin D deﬁciency during pregnancy is prevalent
worldwide, especially in developing countries.8 In a sys-
tematic review of 18 studies conducted in Western coun-
tries during the ﬁrst trimester, white Caucasian pregnant
women were found to have a mean 25(OH)D level
between 29 and 73 nmol/L.9 Mean 25(OH)D levels were
lower in non-Caucasian pregnant women, ranging
between 15.2 and 43 nmol/L.9 In addition to ethnicity,
higher latitude was a signiﬁcant predisposing factor for
hypovitaminosis D.9 Similarly, in non-Western countries,
more than half of the pregnant women who were beyond
their ﬁrst trimester had 25(OH)D levels below 75 nmol/
L; these include countries such as India,10 Kuwait,11
Pakistan12 and Turkey.13 Even lower levels (<25 nmol/L)
have been reported at delivery in Saudi Arabia, Iran and
the United Arab Emirates.14 Furthermore, immigrant
women were at particular risk.15 16 An observational study
from the Netherlands showed signiﬁcantly lower 25(OH)
D levels during the ﬁrst trimester in immigrant pregnant
women (Turkish, Moroccan and others), compared to
western participants.17
Association between maternal vitamin D status and
maternal adverse outcomes
Vitamin D insufﬁciency during pregnancy is associated
with adverse maternal outcomes such as increased risk
of gestational diabetes mellitus (GDM), preeclampsia,
caesarean-section delivery and bacterial vaginosis.18 In a
recent meta-analysis of observational studies, the risk of
GDM was found to be increased by 40–84% in pregnant
women with low 25(OH)D levels, deﬁned as <50 nmol/L
or <75 nmol/L, depending on the studies.19–21 While
preeclampsia risk was signiﬁcantly increased in
vitamin D insufﬁcient women,22 C-section rates were
inconsistently affected by vitamin D status.23 However,
these ﬁndings remain limited by the inherent biases of
observational studies, inconsistent adjustment for con-
founders, in addition to the wide heterogeneity in
vitamin D assays and vitamin D cut-offs deﬁnition.
Association between maternal vitamin D level and
neonatal adverse outcomes
Low maternal 25(OH)D levels were recently linked to
fetal programming, and were found to be associated
with adverse events in neonates, resulting in small for
gestational age (SGA) at birth,19 23 and also later on
during childhood, leading to reduced muscle and bone
mass in offspring at 4 and 9 years.24 25 This may be
explained by the fact that maternal vitamin D is essential
for fetal musculoskeletal integrity, as it regulates neo-
natal bone accrual, possibly through speciﬁc proteins
that are responsible for placental calcium transport.26
Recently, data from the Southampton Women’s Survey
(SWS) showed that maternal 25(OH)D level is signiﬁ-
cantly correlated with placental amino acid transporters
expression, that mediate the transport of various nutri-
ents to the fetus.27 Furthermore, maternal vitamin D
may inﬂuence the fetal muscle motor unit size, and con-
sequently muscle mass and strength after birth.25 It is
noteworthy that fetal bone development is one of the
predictors of peak bone mass, adult bone mineral
content and hip geometry, thus correlating with fracture
risk later in life.26 28
Vitamin D replacement guidelines during pregnancy
The guidelines regarding vitamin D replacement or sup-
plementation during pregnancy vary substantially.
The 2010 Institute Of Medicine (IOM) Report on
Dietary Reference Intakes for Calcium and Vitamin D
recommended 600 IU to pregnant women as the recom-
mended daily allowance (RDA), the RDA being the dose
that is projected to allow at least 97.5% of the pregnant
women population to reach the desirable target 25(OH)
D level ≥50 nmol/L.29 This recommendation was based
on observational studies, none of which were conducted
in the Middle East.29 Conversely, the Endocrine Society
2011 guidelines recommended that 1500–2000 IU daily
of vitamin D is needed to reach a target 25(OH)D level
≥75 nmol/L (a recommendation that was graded as
weak with moderate quality of evidence).30 The
American College of Obstetricians and Gynecologists
(ACOG) does not recommend screening for vitamin D
level in pregnancy, and abides by the IOM recommenda-
tions.31 Moreover, the WHO 2012 guidelines on vitamin
D replacement during pregnancy did not recommend
vitamin D supplementation as part of prenatal care.32
This was based on a meta-analysis of vitamin D trials
during pregnancy, which identiﬁed a limited number of
high-quality studies demonstrating a beneﬁcial effect of
supplementation on maternal and neonatal outcomes,
and concluded that further randomised controlled trials
(RCTs) are needed.33 In the UK, however, pregnant
women are considered at risk of vitamin D deﬁciency,
and supplementation with 400 IU daily is required.34
It is not clear whether any of the above recommended
doses are applicable to non-western populations, with
lower baseline vitamin D levels, such as in Lebanon and
other Middle Eastern countries. Indeed, the WHO
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pregnancy guidelines clearly stated that “Vitamin D sup-
plementation will probably have the most beneﬁt in
populations of poor countries, those with darker skin
colour and in populations with a high prevalence of
vitamin D deﬁciency. It is expected that this intervention
would be acceptable to women who are not exposed to
adequate amounts of sunshine.”32 This is particularly
relevant to our population that tends to avoid sunshine,
wear concealed clothing or use sunblock, all resulting in
the low 25(OH)D levels observed across the life cycle.
RCTs of vitamin D supplementation during pregnancy
Two landmark RCTs have been conducted in the USA35
and the UK.36 Hollis et al35 showed that in pregnant
women in the USA, with a baseline 25(OH)D level
around 60 nmol/L, a vitamin dose of 4000 IU daily
allowed 82% of participants to reach a 25(OH)D level of
80 nmol/L, while only 70% and 50% reached this target
in the intermediate (2000 IU daily) and low (400 IU
daily) doses, respectively. Cooper et al36 showed that
vitamin D supplementation of 1000 IU daily, compared
to placebo, in pregnant women in the UK allowed a sig-
niﬁcant increase in Bone Mineral Content (BMC) of
neonates, however, only when they were born in winter.
One study from India, comparing non-intervention to
vitamin D supplementation groups, with the dose being
dependent on 25(OH)D levels at 20 weeks gestation,
showed that vitamin D supplementation resulted in a sig-
niﬁcant difference in the achieved 25(OH)D level at
delivery (43.1 (81.3) nmol/L in the former group versus
56.8 (47.5) nmol/L in the latter group).37 Hollis et al36
and Sablok et al37 showed that vitamin D supplementa-
tion decreased the risk of preterm labour, gestational dia-
betes and hypertensive complications (all combined).
In the Middle East and North Africa region, there are
few recent RCTs that attempted to determine the
optimal regimen of vitamin D replacement in healthy
pregnant women.38–41 With the exception of
Soheilykhah et al40 who assessed the effect of vitamin D
supplementation on insulin resistance, the primary out-
comes in these studies were mostly maternal and neo-
natal 25(OH)D levels (see online supplementary
appendix 1). None of the other clinically important out-
comes, such as neonatal size and other anthropometric
measurements, neonatal BMC, GDM and C-section
rates, were evaluated as primary outcomes in any of
these trials (see online supplementary appendix 1).
We therefore compiled a registry of all ongoing
vitamin D trials in pregnancy, as captured by their regis-
tration on clinicaltrial.gov42 (see online supplementary
appendix 2). In these trials, different doses of vitamin
D, reaching up to 7000 IU daily, are being administered,
and the outcomes to be assessed include neonatal
weight and length, childhood asthma, maternal bone
mineral density, maternal adverse outcomes, including
preeclampsia and preterm labour, and neonatal adverse
outcomes, such as SGA. Only two of the ongoing trials
are being conducted in the Middle East, one in Iran
and one in Israel, start supplementation in the third tri-
mester and use vitamin D doses of 7000 IU and 2000 IU
daily, respectively. These latter studies aim at assessing
the effect of vitamin D supplementation on offspring
calcium status, maternal and infant vitamin D status and
bone status (by quantitative ultrasound) at 1 year.
Neither addresses the applicability of IOM vitamin D
dose recommendations in pregnant women in the
Middle East. Three completed (unpublished) trials were
identiﬁed (see online supplementary appendix 2), two
from the USA and one from Pakistan. They assessed the
effect of various doses of vitamin D on the 25(OH)D
level, immune function and periodontal disease.
Hypothesis
The study hypothesis is that a high dose of vitamin D,
equivalent to 3000 IU/day, is needed to optimise mater-
nal vitamin D level and neonatal musculoskeletal para-
meters, compared to a low dose of 600 IU/day.
Objectives
The two primary objectives of this trial, comparing the
effect of high-dose versus low-dose vitamin D, are as
follows:
▸ The proportion of women who will reach the IOM
deﬁned desirable 25(OH)D level ≥50 nmol/L at
delivery.
▸ Infant BMC at 1 month.
The secondary objectives are to compare the effect of
high-dose versus low-dose vitamin D on:
▸ Maternal outcomes:
– Mean maternal 25(OH)D level at delivery.
– Mean maternal PTH level at delivery.
– Mean change in maternal urine calcium.
▸ Neonatal outcomes:
– Mean neonatal 25(OH)D level at delivery.
– Mean neonatal PTH level at delivery.
– Mean neonatal fat and lean mass at 1 month.
– Mean neonatal knee to heel length at birth.
Exploratory outcomes include a composite outcome
(incidence of GDM and C-section), maternal weight,
blood pressure, ill days, fetal and neonatal anthropomet-
ric measures, including neonatal length and weight, rate
of small for gestational age, APGAR score, placental
weight and 1α-hydroxylase activity, in addition to other
placental and genetic studies, that characterise mineral
and fuel metabolism.
METHODS AND ANALYSIS
The protocol of this trial was developed on the basis of
Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT); see online supplemen-
tary appendices 3–6 for further details. This protocol is
registered on clinicaltrial.gov (NCT 02434380, April
2015).
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Study design
This study is a phase III multicentre blinded randomised
controlled superiority trial with two arms, conducted at
the American University of Beirut—Medical Center
(AUB-MC), Raﬁc Hariri University Hospital (RHUH)
and Bahman Hospital.
Recruitment
Pregnant women in their ﬁrst trimester will be recruited
from the obstetric private clinics and outpatient depart-
ments of the three participating centres (AUB-MC,
RHUH and Bahman Hospital). Information about the
trial will be available as Arabic and English ﬂyers in the
obstetrics and gynaecology department, as well as
the private clinics and outpatient departments of the
three centres. The ﬂow chart of participants and details
of study visits are summarised in ﬁgure 1.
Randomisation
The allocation sequence will be a computer-generated,
permuted block randomisation, stratiﬁed by study
centre, with a 1:1 allocation. The statistician will be
responsible for sequence generation and treatment
assignment. The senior pharmacist at AUB-MC will be
responsible for treatment allocation.
Concealment and blinding
Vitamin D and placebo pills are manufactured to have a
similar shape, colour, size, smell and taste. The study
medications will be stored at the AUB-MC pharmacy,
and placebo and/or vitamin D pills will be dispensed in
boxes. Boxes will be sequentially numbered as per the
random allocation list by the pharmacist. The pharma-
cist keeps the list linking the randomisation code to the
participant identity/trial number and to the delivered
box number. At each visit, the pharmacist allocates a
box to every participant, containing enough pills until
the next visit, with dates at which pills should be admi-
nistered. The research assistant collects the boxes in
sealed envelopes prior to each participant’s visit and
delivers them at the end of the visit.
The research assistants, the healthcare providers, the
principal investigator, the co-investigators and the bio-
statistician do not have access to code break, and are all
blinded to the treatment allocation. The only personnel
who will not be blinded will be the pharmacist.
Investigational medicinal product
All participants receive once per week two tablets that
are similar in shape, colour, size, smell and taste. Each
tablet can be either a placebo or a 10 000 IU vitamin D
(cholecalciferol), provided by Europharm.
The high-dose group receives two tablets of 10 000 IU
weekly (equivalent daily dose 2857 IU).
The low-dose group receives one tablet of 10 000 IU
and one tablet of placebo alternating with two tablets of
placebo on a weekly basis (equivalent daily dose
714 IU).
Vitamin D supplementation present in prenatal multi-
vitamins will be permitted up to 200 IU daily, which will
raise the aforementioned treatment doses to approxi-
mately 3050 IU and 900 IU daily, respectively.
The manufacturers had no role in the study design or
implementation.
Study visits
A. Prescreening visit
Trained research assistants will approach pregnant
women who are in their ﬁrst trimester during their
routine prenatal visits to study sites. Eligible pregnant
women willing to participate and to be compliant with
the study protocol, and who provide written informed
consent, will be invited to a screening visit.
B. Screening visit
The screening visit will be scheduled to coincide with
the nuchal translucency appointment date (between 11
and 13 weeks of gestation). During this visit, eligibility
criteria will be veriﬁed and blood tests for 25(OH)D
level, calcium, phosphate, magnesium, creatinine and
thyroid stimulating hormone (TSH) will be withdrawn.
Urine calcium will be assessed in a fasting urine spot or
24 h urine collection (table 1). The level of 25(OH)D
will be measured using the electrochemiluminescence
immunoassay (ECLIA) at the AUB-MC Clinical
Chemistry laboratory. Reference ranges using this assay
are deﬁned as follows: Deﬁciency <25 nmol/L, insufﬁ-
ciency 25–62.4 nmol/L, desirable >62 nmol/L, toxic
>374 nmol/L. AUB-MC clinical chemistry laboratory par-
takes in the quality assurance, evaluation and accredit-
ation by the College of American Pathologists43 and is a
participant in the Vitamin D External Quality Assurance
Surveillance (DEQAS) programme.44
Eligibility criteria
Inclusion criteria:
▸ Pregnant women gestational age (GA) <14 weeks at
screening visit.i
▸ Middle Eastern origin; Middle East countries as
deﬁned by the World Bank (Bahrain, Egypt, Iran,
Iraq, Palestine, Jordan, Kuwait, Lebanon, Oman,
Qatar, Saudi Arabia, Syria, the United Arab Emirates,
Yemen).45
▸ 25(OH)D level between 25 and 75 nmol/L.
▸ Age >18 years.
Vitamin D supplementation ≤200 IU daily.ii
Exclusion criteria:
iIn the case where the pregnant woman presents after 13 weeks GA,
she is still eligible for the screening visit provided that screening blood
tests are carried out before 16.5 weeks of gestation and the ﬁrst visit in
the trial occurs before 18 weeks GA.
iiIf daily vitamin D supplementation is between 200 and 600 IU daily, at
enrollment, the pregnant women will be advised to adjust prenatal
multivitamin doses, in consultation with her primary obstetrician, to
ensure that total vitamin D supplementation during the study does not
exceed 1400 IU/week, in consultation with the primary obstetrician.
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▸ 25(OH)D level <25 nmol/L, as it would be unethical
to randomise pregnant women to the low dose of
vitamin D, and 25(OH)D level >75 nmol/L (30 ng/
mL), as vitamin D supplementation with routine pre-
natal multivitamins would be sufﬁcient.
▸ Known metabolic bone disease or chronic diseases
associated with bone abnormalities (renal or liver
diseases.
▸ Current medications likely to interfere with vitamin D
metabolism (enzyme inducing anticonvulsants,
antituberculosis).
▸ Vitamin D supplementation >600 IU daily.iii
▸ Fetal physical anomalies on the initial ultrasound.
▸ Renal stones.
▸ Hyperparathyroidism.
▸ Uncontrolled thyroid dysfunction.
▸ Diagnosis of cancer in the past 10 years (other than
basal cell carcinoma).
▸ Serum calcium >10 mg/dL.
▸ Diabetes mellitus type 1 or type 2.
▸ Previous GDM.
▸ Allergy to any component of vitamin D formulation.
C. First visit
During the ﬁrst visit at 15–18 weeks GA, a question-
naire will be administered to collect maternal informa-
tion on parity, demographics, smoking and alcohol
history, exercise, previous medical problems, medica-
tions, dietary calcium and vitamin D intake, in addition
to relevant paternal information. Pregnant women will
Figure 1 Trial flow chart. BMD, bone mineral density.
iii*If a pregnant woman is on a high dose of vitamin D
supplementation, > 600 IU daily, vitamin D should be stopped at least
1 month prior to study entry, at the discretion of her primary
physician.
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Table 1 Trial events and outcomes measures
Trial event and outcomes measures
11–13 weeks
(screening
visit)
15–18 weeks
(visit 1) 20 weeks 24–28 weeks
28–32 weeks
(visit 2)
37–42 weeks
Delivery
(visit 3)
1 month
post partum
(visit 4)
Maternal height ✓
Maternal weight, blood pressure ✓ ✓ ✓
Maternal health and diet assessment ✓ ✓ ✓
Maternal 25(OH)D, Crea, Ca × × ×
Maternal cell count, ph, mg, alb, TSH, 1,25(OH)2D ×
PTH × ×
Maternal glucose (1 h) ✓
Maternal 24 h (or spot) urine collection for calcium and
creatinine
× ×
Maternal vitamin D binding protein × ×
Maternal genetic pathways of vitamin D metabolism ×
Fetal US:
▸ crown -rump
✓
Fetal US:
▸ Femur length
▸ Abdominal circumference
▸ Head circumference
▸ Biparietal diameter
✓
Newborn weight, length, knee to heel length APGAR score ✓
Placental weight ×
Placental studies ×
Newborn 25(OH)D, Ca, PTH (cord blood) ×
Newborn genetic pathways of vitamin D metabolism ×
Infant bone/fat mass ×
Infant weight and length ✓
Infant health and diet assessment ✓
✓Test performed for clinical purpose.
×Test performed for research purpose.
PTH, parathyroid hormone; TSH, thyroid-stimulating hormone; US, ultrasound
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be randomised early in their second trimester to one of
two vitamin D doses as discussed above.
D. Second visit
This visit will take place at 28–32 weeks GA, during
which maternal weight and blood pressure will be
recorded, maternal health and diet assessed, in addition
to assessment of adverse events, if any. We will check
compliance to trial medication by pill counting. Blood
and urine tests will be carried out (see table 1).
E. Third visit
The third visit will coincide with the participant’s
delivery. When entering labour, the research team will
be informed about each participant by the obstetrician,
or by the participant, or her partner. The research assist-
ant will visit the participant on the ﬁrst day post partum,
and will record information on delivery mode, delivery
course and complications, if any. In addition, neonatal
measurements at birth such as length, weight and knee
—heel length will be recorded in triplicate. Knee-heel
length will be measured using handheld vernier cali-
pers.46 Knee—heel length measurement is operator
dependent; hence, measurements will be carried out in
triplicate, and only by paediatricians/neonatologists who
are trained on how to use such instruments.
The neonatal 25(OH)D level will be obtained from
cord blood, whereas maternal blood tests will be with-
drawn when the pregnant woman presents in labour. In
addition, blood tests at delivery include genetic studies
such as vitamin D genes polymorphism and RNA expres-
sion of vitamin D polymorphisms. After delivery, placental
sampling will be performed by a trained medical doctor
and samples will be preserved and stored at −80°C.
F. Fourth visit
This visit will occur when the infant is 1 month of age.
He will undergo bone mineral density (BMD) assess-
ment by dual-energy X-ray absorptiometry (DXA) scan,
Hologic machine, Horizon A, V.13.5.3.1, at AUBMC.
Infant DXA assessment is performed by technicians
certiﬁed by the International Society for Clinical
Densitometry (ISCD). The technician positions the laser
light so that it is centred about 2 cm below the iliac crest
(or umbilicus/belly button) on the child, and observes
the emerging image to ensure that the spine is centrally
positioned and straight, and that the top of the iliac
crests and all of L5 are visible.
In addition, during this visit, information about the
infant’s health and feeding will be recorded using an
interviewer-led questionnaire.
Sample size calculation and justification
Sample size was calculated for the two primary out-
comes: the proportion of pregnant women who will
reach a 25(OH)D ≥50 nmol/L at delivery, and the
infant BMC at 1 month; the largest number was consid-
ered the ﬁnal sample size. Given that we have two
primary outcomes, type I error was considered 2.5%.47
Sample size calculation was performed online.48
Sample size calculation for the proportion of women
who will reach a 25(OH)D ≥50 nmol/L at delivery
On the basis of a retrospective lab study conducted at
AUB-MC in 2014, the median 25(OH)D level in the
Lebanese population was found to be 52 nmol/L
(20.9 ng/mL). The low-dose group will receive 10 000 IU
vitamin D weekly, equivalent to 700 IU daily. The high-
dose group will receive 20 000 IU vitamin D weekly,
equivalent to 2850 IU daily. Considering that each
100 IU vitamin D supplementation increases the level by
1.7 nmol/L,49 the expected levels reached in the
low-dose and high-dose arms would be 67 nmol/L and
106 nmol/L, respectively. This computation takes into
consideration that all groups will be taking additional
200 IU vitamin D daily from their prenatal vitamin pills,
thus increasing the ﬁnal vitamin D intake approximately
to 900 IU/day in the low-dose group and 3050 IU/day in
the high-dose group. The expected proportions of preg-
nant women who would reach a 25(OH)D level
≥50 nmol/L, using a SD of 24.9 nmol/L, and assuming
normality, would be 75% and 98.4%, in the low-dose and
high-dose arms, respectively. To detect statistical signiﬁ-
cance between the two groups, for a 90% power and a
type I error of 2.5%, 50 participants per arm are needed.
Calculation was also carried out on the basis of the
results of a recently completed systematic review and
meta-analysis of RCTs from the Middle East and North
Africa (MENA), conducted by Chakhtoura et al, as part of
a Master of Sciences in Health Research thesis project
(available online from the Jafet Library at the American
University of Beirut—Lebanon). Thismeta-analysis showed
that, in pregnant women from the MENA region, a vitamin
D dose of 800–2000 IU daily results in an increase in the
25(OH)D level by 2.5 nmol/L, and a high dose of
>2000 IU daily results in an increase in the 25(OH)D level
by 1.67 nmol/L. Starting from a baseline 25(OH)D level
of 52 nmol/L, the 25(OH)D levels achieved would be
74.5 nmol/L and 103 nmol/L in the low-dose and high-
dose groups, respectively. Accordingly, 83.6% and 98.3%
would reach the target 25(OH)D level of 50 nmol/L, and
72 participants per arm are needed for an 80% power and
a type I error of 2.5%. It is noteworthy that the studies
included in the aforementioned meta-analysis had a base-
line 25(OH)D level of 20–27 nmol/L, lower than the
expected levels in our participants.
Sample size calculation for infant BMC
Estimations were based on the preliminary results of the
MAVIDOS trial conducted by our collaborators at
Southampton University, UK. They showed a signiﬁcant
difference of 6 g (SD 10 g) in neonatal mean BMC in
the vitamin D supplemented group, compared to
placebo, in the winter season.36 For a 90% power and a
type I error of 2.5%, considering an SD of BMC of 10 g,
to detect a 6 g difference in BMC between high-dose
and low-dose groups, 69 participants per arm are
needed. Taking into consideration that 25(OH)D levels
in RHUH and Bahman hospital are lower compared to
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pregnant women presenting to AUB-MC and to preg-
nant women in the UK, a signiﬁcant improvement in
BMC is expected throughout the year in the high-dose
group compared to the low-dose group.
The largest sample size of 69 participants per arm is
our target. If we consider a 50% dropout rate, to be con-
servative, approximately 140 participants per arm should
be recruited for a total of 280 pregnant women for the
whole study. If we consider that 50% of pregnant women
presenting to clinics are eligible, approximately a total
of 560 pregnant women should be screened initially. If
30% of pregnant women accept to participate in clinical
trials, approximately 1870 pregnant women should be
approached initially.
Statistical analysis
Baseline demographic characteristics will be summarised
using frequencies and percentages for categorical
characteristics, and mean ±SD (or median and range)
for continuous variables. Normality of all variables will
be checked. Comparisons between dose groups will be
performed using χ2 tests for categorical variables, and t
test for continuous variables, as appropriate.
Unadjusted analysis
Two primary outcomes are considered:
A. The proportion of women who reach a 25(OH)D
≥50 nmol/L: binary outcome; the percent of women
achieving 25(OH)D ≥50 nmol/L in the low dose will
be compared to those in the high dose using χ2, by
constructing a 95% CI for the difference and com-
puting an unadjusted RR and its 95% CI, along with
the p value. A number needed to treat (NNT) will
also be computed.
B. The mean infant BMC at 1 month: continuous
outcome; an independent t test will be used to
compare mean BMC between the two arms. 95% CI
for the difference will be calculated.
Secondary and exploratory outcomes:
For secondary and exploratory outcomes, a t test will
be used for continuous outcomes and χ2 will be used for
binary outcomes to compare means and proportions,
respectively. Non-parametric tests including the
Wilcoxon sign rank test and Fisher’s exact test will be
used, respectively, instead of t test and χ2, when needed.
Relative Risk (RR) with corresponding CIs will be cal-
culated for dichotomous variables, and difference in
means with their 95% CIs will be used for additional
analysis of continuous variables.
The primary analysis is an intention-to-treat analysis
(ITT) of unadjusted results, ITT being deﬁned as the
analysis of all participants as randomised, regardless of
whether they respected the study protocol or not (effect-
iveness). The p values will be reported to four decimal
places.
For the primary outcomes, p values will be considered
statistically signiﬁcant if ≤0.025.
SPSS V.23 will be used to conduct statistical analysis.
In case of missing data, analysis restricted to results of
individuals with complete data will be carried out (with
retrospective power calculation) and compared to ana-
lysis resulting from multiple imputations to try to test
the robustness of results.50
Additional analysis
Subgroup analysis
As discussed earlier, the IOM targets a 25(OH)D level of
≥50 nmol/L29 and the Endocrine Society targets a level
of ≥75 nmol/L.30 Subgroup analysis based on a 25(OH)
D level at study entry (<50 nmol/L vs ≥50 nmol/L) will
be carried out to explore whether the treatment effects
persist across all 25(OH)D categories, whether below or
above 50 nmol/L.
Subgroup analysis based on the season will be also per-
formed to check for interaction between the vitamin D
dose and the season of pregnant women enrolment.
Sensitivity analysis
Sensitivity analysis will be performed, including Per
Protocol analysis and as treated analysis. In addition, an
adjusted analysis will be performed, including adjustment
for variables that are not evenly distributed between the
two arms, if any, and adjustment for variables that are
clinically important (even if there is no imbalance in the
baseline characteristics of the 2 groups); this includes the
baseline 25(OH)D level, pre-pregnancy body mass index,
season at enrolment and smoking status.
Ethical considerations
We will restrict enrolment to pregnant women whose 25
(OH)D levels range between 25 and 75 nmol/L. This is
because it will be unethical to include women with levels
<25 nmol/L in the trial, as there is a risk to randomly
allocate them to the low-dose arm. In addition, women
with a 25(OH)D level >75 nmol/L will be excluded in
order to prevent reaching supranormal levels of 25(OH)
D should they be allocated to the high-vitamin D dose.
It is noteworthy that high doses of vitamin D (up to
4000 IU daily) have been used in previous trials con-
ducted during pregnancy with no reported adverse
events (see online supplementary appendix 1).
The infant radiation exposure resulting from the study
procedure, BMD testing by DXA, is minimal. The radi-
ation dose is estimated at 0.007 mSv for whole body
DXA. This dose is equivalent to 20 h of exposure to
background radiation, based on the Duke Radiation
Safety online assessment and statement.51
Safety considerations
Information on adverse events will be regularly collected
soon after starting the trial intervention and during each
trial visit. In between visits, all participants will be called
by the research team every 2 weeks to emphasise compli-
ance with treatment regimens and to enquire about
adverse events. All information will be documented in
case report forms and discussed with the Trial
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Monitoring Committee (TMC) (see online supplemen-
tary appendix 3 for further details). The TMC will report
any serious adverse event to IRB and the Data Safety and
Monitoring Board (DSMB) within 48 h.
Dissemination
Trial results will be communicated to participants, to the
public, and to healthcare professionals at AUB-MC and
in Lebanon. Results will be presented in scientiﬁc meet-
ings and conferences and published in peer-reviewed
medical journals, whether the results are in the
expected direction or not.
DISCUSSION
Hypovitaminosis D is a well-recognised common public
health problem in Lebanon and in most countries of
the Middle East. Many observational studies suggest that
maternal hypovitaminosis D is associated with adverse
maternal and neonatal outcomes. Vitamin D RCTs in
pregnancy are scarce, with small sample sizes, and their
primary outcomes are mostly limited to measuring 25
(OH)D levels in mothers and neonates. Furthermore,
given the lack of evidence-based guidelines that deﬁne
the optimal RDA for vitamin D supplementation during
pregnancy in our population, and the limited number
of randomised clinical trials completed so far in our
region, this trial will ﬁll an important knowledge gap.
We will conduct this RCT to test the impact of two differ-
ent doses of vitamin D replacement on clinically relevant
maternal and neonatal outcomes in Middle Eastern
women. The Lebanese and other Middle Eastern
women in the reproductive age are ideally suited for
such trials, in view of the fact that the median 25(OH)D
levels in this age group is relatively low. These levels are
reﬂective of the median low levels registered in most
countries from the Middle East, as well as those from
Northern Africa.14 The doses used will allow us to dir-
ectly address the applicability of the IOM in our region.
The ﬁndings of this trial will help guide the public
health policymaker regarding vitamin D supplementa-
tion in pregnant women and will allow a step forward in
evidence-based recommendations speciﬁc to the Middle
East. Multiple outcomes that have never been targeted
in any previous trial in pregnancy will be assessed as sec-
ondary or exploratory outcomes; indeed, the results will
guide future research projects in this ﬁeld.
Findings from our trial, and similar to results derived
from nutrient RCTs, are prone to the confounding
effect of several factors.52 Indeed, the baseline 25(OH)D
level, the dietary intake of vitamin D and other nutri-
ents, such as calcium and proteins, sun exposure and
others, remain important predictors affecting the
response to vitamin D supplementation, but are very dif-
ﬁcult to quantify accurately.
Trial status
The study was launched on 27 July 2015.
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